We are so proud to be a part of the kit development. All our tech transfer expertise has been successfully implied in the process.

“The new antibody test and its anticipated market launch represents not only a great success for Czech science but also for the offices professionally engaged in the translation of research results into practice, from initial patent protection and preparation of the project to identification of an industrial partner and finalization of the licensing terms,” says Martin Fusek, director of IOCB Tech.